Rankings Pharma & medtech Coloplast
Coloplast
57
15070100
A view of the same findings, not a new score. How it works
A good business with a real question mark: the price, a crack, or both.
Biggest deductions
- Regulation−6
- Capital allocation−5
- Margin−4
Strengths
- Insider buying+3
- Cash flows+2
How the score is built
From 100 to 57, step by step: points off for the business, the price and the cracks, back for documented strengths, then three data adjustments.
Start
Score
Hover or select a step to see what drove it. Steps with findings open them below.
Key numbers
As of 3 Nov 2026. Analyst targets tend to be optimistic; read upside as a hint, not a forecast.
- Price
- 468.10 DKK
- Median analyst target
- 455.00 DKK
- Upside to median
- −2.8%
- Analysts
- 21
- Target range
- 377.00 – 575.00 DKK
- 52-week change
- −19%
- P/E (trailing)
- 34.3
- Forward P/E
- 19.7
- PEG
- 2.39
Findings
Every deduction and every plus, with its source. Open a step to read them.
Business
Is the company getting stronger, not just bigger? · 3 findings−12 of −30
- −4MarginEBIT margin before special items is 26% in 9M 2025/26 vs 27% a year earlier and 32–33% a few years ago. The new 5-year targets promise no margin improvement.
- −5Capital allocationROIC has fallen from 52% (2020/21) to about 15% after the debt-funded acquisitions of Atos Medical and Kerecis; net debt is DKK 23bn vs 2bn in 2021.
- −3Quality of growthThe growth target has been cut from 8–10% to 7–8% a year, and realised organic growth is only 6% in 9M; Wound & Tissue Repair is growing 2%.
Price
Today's multiples against the company's own history and its peers. · 1 finding−2 of −35
- −2Multiples vs own historyForward P/E 16.4 and EV/EBITDA 13.2 are the lowest in at least five years (27–41 and 17–32 in 2021–25). But trailing P/E is 34, leverage 2.7×, and the low multiple reflects lower growth.
Cracks
Cash flow, customers, debt, insiders, guidance and what sits behind the headline numbers. · 4 findings−16 of −35
- −6RegulationChanged Medicare reimbursement rules for skin substitutes in the US triggered a DKK 3bn write-down of Kerecis; the business is now expected to deliver about 0% growth and about 0% EBIT margin. In April growth guidance was cut from about 7% to 5–6%.
- −4Management changeCEO Kristian Villumsen left unexpectedly in spring 2025, and the chairman stepped in as interim CEO. Gavin Wood only took over in March 2026, and the board is now led by an interim chair.
- −4Debt and dividendNet debt DKK 23bn (2.7× EBITDA). The dividend of DKK 23 equals 188% of net profit and 83% of FCF, and analysts expect it to be cut to about DKK 20.
- −2Share price trendThe share price has halved since the 2022 peak and fallen 24% over 52 weeks; 15 of 21 analysts rate it hold and 3 sell.
Plus
Only documented strengths. · 2 findings+5 of +15
- +3Insider buyingThe interim chair has bought shares for almost DKK 0.9m; a new board member and the CFO have also bought (May 2026).
- +2Cash flowsFree cash flow has risen to 20% of revenue in 9M vs 16% a year earlier; FCF is DKK 6.3bn (TTM).
Caveats
What the score does not capture, or where the data is weak.
Kerecis impairment (DKK 3bn) weighs on the trailing P/E; new CEO since March 2026 and an interim chair; dividend above net income
Also in Pharma & medtech
The highest scores in the same industry.
